Patents by Inventor Benjamin Szwergold

Benjamin Szwergold has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for inhibiting or reversing non-enzymatic glycation
    Patent number: 8138227
    Abstract: The present invention relates to a method for inhibiting or reversing non-enzymatic glycation of the first intermediate of a biological moiety using an ?-thiolamine. By inhibiting or reversing non-enzymatic glycation of the biological moiety, conditions such as aging and diabetic complications can be prevented or reversed.
    Type: Grant
    Filed: June 1, 2007
    Date of Patent: March 20, 2012
    Assignee: Trustees of Dartmouth College
    Inventor: Benjamin Szwergold
  • Method for inhibiting or reversing non-enzymatic glycation
    Publication number: 20080009547
    Abstract: The present invention relates to a method for inhibiting or reversing non-enzymatic glycation of the first intermediate of a biological moiety using an ?-thiolamine. By inhibiting or reversing non-enzymatic glycation of the biological moiety, conditions such as aging and diabetic complications can be prevented or reversed.
    Type: Application
    Filed: June 1, 2007
    Publication date: January 10, 2008
    Inventor: Benjamin Szwergold
  • Compounds and methods for therapeutic intervention in preventing diabetic complications and procedures for assessing a diabetic's risk of developing complications and determining the efficacy of therapeutic intervention
    Patent number: 6004958
    Abstract: The present invention is based on the discovery of a metabolic pathway in which a specific kinase converts fructose-lysine into fructose-lysine-3-phosphate in an ATP dependent reaction. Fructose-lysine-3-phosphate (FL3P) is then broken down to form free lysine, inorganic phosphate and 3-deoxyglucosone (3DG), the latter being a reactive protein modifying agent. 3DG can be detoxified by reduction to 3-deoxyfructose (3DF), or it can react with endogenous proteins to form advanced glycation end-product modified proteins (AGE-proteins), which are believed to be a cause of diabetic complications. Disclosed is a class of compounds which inhibit the action of FL3P kinase in the above-mentioned pathway.
    Type: Grant
    Filed: February 5, 1997
    Date of Patent: December 21, 1999
    Assignee: Fox Chase Cancer Center
    Inventors: Truman R. Brown, Francis Kappler, Benjamin Szwergold, Sundeep Lal, Bangying Su